Recent Amendments to Foreign Direct Investment Regulations – Expansion of Designated and Core Business Sectors

著者等: 服部纮实

全文下载（PDF）

出版社: 长岛・大野・常松律师事务所

书籍名或刊登 杂志: NO&T Japan Legal Update 第29号（2021年9月）

语言: 英文

相关信息

业务领域

请注意，本简报的目的是提供信息，并非提供法律建议。另外，本简报仅包括根据发行日(制作日)时点的信息，不包括该时点之后的信息。特别是速报可能会与现状的解释或惯例不同，敬请留意。

I. Introduction
Over a year has passed since the amendment to the Foreign Exchange and Foreign Trade Act (the “FEFTA”) and its related cabinet orders, ministerial ordinances and public notifications (collectively, the “2019 Amendment”) entered into force on May 8, 2020.
On June 15, 2020, the Japanese government added the manufacturing of pharmaceuticals for specific infectious diseases as well as the manufacturing of specially-controlled medical devices to the list of business sectors that require advance filing under Japanese foreign direct investment (“FDI”) regulations under the FEFTA (“designated business sectors”). In addition, those business sectors were also designated as “core business sectors” because of their strategic value from a national security perspective. Entities purporting to acquire up to 10 percent of a listed company in a core business sector are subject to more stringent criteria when applying for an exemption from making advance filings, and are not eligible for any exemption from making advance filings for share acquisitions of an unlisted company.
On August 18, 2021, the Japanese government announced its plan to add business sectors relating to rare-earth metals to the list of designated and core business sectors.
This article outlines the Japanese government’s recent movements to expand the scope of more stringent FDI regulations to new business sectors.

下载PDF